2022-11-08 | NYSE:TAK | Press release

Funding will support the first active, multicenter, randomized comparator trial to assess the optimal first-line treatment strategy for ileal Crohn’s disease

TORONTO, November 8, 2022 /CNW/ – Inflammatory Bowel Disease Research Consortium of Canada (IARC) Awards Inaugural Award $1 million PIONEER grant from Takeda Canada Inc. (Takeda), in support of high-quality, impactful Canadian clinical research aimed at improving patient outcomes and quality of life for people living with inflammatory bowel disease ( IBD).

The grant recipient will also receive support from Alimentiv, a world-class research organization with deep expertise in conducting IBD clinical trials, through its expertise, research execution and in-kind support.

With the support of Crohn’s and Colitis Canada, IARC was created in 2017 to attract and facilitate clinical studies in Canada creating a collaborative network of clinician-scientists and providing research support.

This year’s recipient is Dr. Christopher Mathe principal investigator of PATHFINDER: A pragmatic, active-comparator, parallel-group, randomized trial to assess the optimal first-line treatment strategy for moderate to severe active ileal Crohn’s disease.

IBD causes chronic inflammation of the gastrointestinal (GI) tract that impacts food digestion, nutrient absorption, and waste disposal for those affected.I The main forms are Crohn’s disease (CD) and ulcerative colitis (UC). More than 300,000 Canadians live with this disease for which there is currently no cure.ii

Most CD patients have inflammation in the last part of the small intestine, called the ileum. Ileal DC increases the risk of intestinal damage. It is therefore essential to choose the right medical treatment to prevent complications such as hospitalization and surgery.

Dr Ma, along with his colleagues Dr. Remo Panaccionedr. Vipul JairathDr Talat Bessissiow, Dr. Cathy LuDr. GY Zou, and Dr. Susan Elliotwill conduct the first multicenter, pragmatic, randomized trial that directly compares which of three classes of biologics (anti-TNF, anti-integrin, and anti-IL-12/23) is optimal for achieving intestinal healing (endoscopic remission) at a given time an .

Quotation:

“This is the first clinical trial to determine which class of biologics is the optimal first-line treatment for patients with high-risk ileal Crohn’s disease,” said dr. Christopher Maearly career researcher and academic gastroenterologist at the Cumming School of Medicine, University of Calgary. “We hope the results from PATHFINDER will provide physicians with evidence-based treatment decisions to ensure better outcomes and improved quality of life for patients.”

“The PIONEER grant is an outstanding example of how we can develop high-quality scientific research on IBD through collaboration and partnerships,” said dr. Neeraj NarulaPresident, CRIA. “The PATHFINDER research project has the opportunity to provide practice-changing evidence to optimize patient outcomes led by Canadian researchers.”

“At Takeda, we are committed to advancing scientific research in the field of IBD and are proud to establish the IARC PIONEER grant to support Canadian researchers in their pursuit of life-changing innovations,” said Rute FernandesGeneral director, Takeda Canada. “We commend Dr. Ma and his team for identifying this unique clinical need that could have a significant impact on patients with ileal Crohn’s disease.”

About Crohn’s and Colitis Canada

Crohn’s and Colitis Canada continues a relentless journey to find the cures for Crohn’s disease and ulcerative colitis and improve the lives of all those affected by these chronic diseases. Collectively, with the support of volunteers, researchers, donors and the community, we transform the lives of people affected by Crohn’s disease and colitis through research, support programs, advocacy and awareness. For more information, visit crohnsandcolitis.ca and follow us @getgutsycanada on Twitter, Facebook and Instagram.

About the Canadian Consortium for Inflammatory Bowel Disease Research (IARC)

IARC was founded in 2017 through a partnership with Crohn’s and Colitis Canada. IARC is made up of Canadian gastroenterologists with a particular interest in IBD. Over the past five years, the organization has grown to include more than 60 Canadian gastroenterologist members who collaborate in multicenter IBD clinical research, with a particular focus on multicenter investigator-initiated trials, as well as on generating real-world evidence.

About Takeda Canada Inc.

Takeda Canada Inc. is the Canadian organization of Takeda Pharmaceutical Company Limited (TSE: 4502) (NYSE: TAK), a global leader in values-based biopharmaceutical research and development, headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our employees and the planet. Takeda focuses its R&D efforts on four therapeutic areas: oncology, rare genetics and hematology, neurosciences and gastroenterology (GI). We also make targeted R&D investments in plasma-derived therapies and vaccines. We are focused on developing highly innovative medicines that help make a difference in people’s lives by pushing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust pipeline and diversified in terms of modalities. Our employees are committed to improving the quality of life for patients and working with our healthcare partners in approximately 80 countries and regions. For more information visit: takeda.com/en-ca.

About Alimentiv Inc.

Alimentiv is a global contract research organization (CRO) providing clinical trials, centralized image management, precision medicine and real-world evidence services to the pharmaceutical and biotechnology industries. Based at London, Ontario. Alimentiv is committed to investing in medical research and development, focusing on identifying barriers to drug development and seeking solutions that advance IBD research. Research findings are operationalized into a client-effective clinical trial methodology that aligns with emerging regulatory standards. Together with leading experts, Alimentiv has pioneered the development, validation and standardization of outcome measures and technology, shaping the evolving landscape of clinical trials for multiple indications and delivering meaningful consequences. long term for patients, their treatment and society. For more information visit: www.alimentiv.com

From left to right: Dr. Christopher Ma, Rute Fernandes, Managing Director, Takeda Canada, and Dr. Neeraj Narula, President, IARC.  (CNW Group/Crohn's and Colitis Canada)

Crohn's and Colitis Canada Logo (CNW Group/Crohn's and Colitis Canada)

SOURCE Crohn’s and Colitis Canada

Quote Show original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2022/08/c3991.html